Live Breaking News & Updates on Neurosciences Stock Down

Stay updated with breaking news from Neurosciences stock down. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Minerva Neurosciences (NASDAQ:NERV) Raised to "Hold" at StockNews.com

Minerva Neurosciences (NASDAQ:NERV) Raised to "Hold" at StockNews.com
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Minerva Neurosciences , Minerva Neurosciences Company Profile , Minerva Neurosciences Inc , Free Report , Neurosciences Stock Down , Get Free Report , New Drug Application , Minerva Neurosciences Daily ,

HC Wainwright Comments on Minerva Neurosciences, Inc.'s FY2028 Earnings (NASDAQ:NERV)

Minerva Neurosciences, Inc. (NASDAQ:NERV – Free Report) – Stock analysts at HC Wainwright issued their FY2028 earnings per share (EPS) estimates for Minerva Neurosciences in a research note issued on Friday, February 23rd. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company will post earnings per share of $0.90 for the year. HC Wainwright […] ....

Minerva Neurosciences , Geode Capital Management , Minerva Neurosciences Inc , Northern Trust Corp , Jpmorgan Chase Co , Renaissance Technologies , Free Report , Minerva Neuroscience , Neurosciences Stock Down , Get Free Report , Capital Management , New Drug Application , Minerva Neurosciences Daily , Nasdaq Nerv , Earnings Estimates , Hc Wainwright ,

Minerva Neurosciences (NASDAQ:NERV) Upgraded to "Hold" by StockNews.com

StockNews.com upgraded shares of Minerva Neurosciences (NASDAQ:NERV – Free Report) from a sell rating to a hold rating in a research note published on Friday. Separately, HC Wainwright upped their price objective on shares of Minerva Neurosciences from $8.00 to $11.00 and gave the company a neutral rating in a report on Wednesday, August 2nd. […] ....

Minerva Neurosciences , Minerva Neurosciences Inc , Renaissance Technologies , Blackrock Inc , Geode Capital Management , Jpmorgan Chase Co , Virtu Financial , Free Report , Neurosciences Stock Down , Get Free Report , Capital Management , New Drug Application , Minerva Neurosciences Daily , Nasdaq Nerv , Stocknews Com ,

Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Down 20.3% in September

Minerva Neurosciences, Inc. (NASDAQ:NERV – Get Free Report) saw a large decrease in short interest during the month of September. As of September 30th, there was short interest totalling 59,000 shares, a decrease of 20.3% from the September 15th total of 74,000 shares. Based on an average trading volume of 45,200 shares, the days-to-cover ratio […] ....

Minerva Neurosciences , Minerva Neurosciences Inc , Virtu Financial , Renaissance Technologies , Minerva Neurosciences Company Profile , Blackrock Inc , Geode Capital Management , Get Free Report , Neurosciences Stock Down , Capital Management , New Drug Application , Minerva Neurosciences Daily , Nasdaq Nerv ,

Minerva Neurosciences (NASDAQ:NERV) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Rating) in a research report sent to investors on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Separately, HC Wainwright reissued a neutral rating and set a $8.00 price objective on shares of Minerva Neurosciences in a report on Thursday, […] ....

Minerva Neurosciences , Remy Luthringer , Securities Exchange Commission , Blackrock Inc , Renaissance Technologies , Minerva Neurosciences Inc , Get Rating , Neurosciences Stock Down , President Geoff Race , Exchange Commission , New Drug Application , Minerva Neurosciences Daily , Nasdaq Nerv , Initiated Coverage , Stocknews Com ,